Enlivex Announces Favorable 12-Month Topline Data from Phase I/IIa Allocetra Trial, Demonstrating Durable Treatment ResponseGlobeNewsWire • 11/02/26
Enlivex Announces Randomization of 135 Patients in Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee OsteoarthritisGlobeNewsWire • 10/28/26
Enlivex Announces 1-for-16 Reverse Share Split to be Effective October 27, 2026GlobeNewsWire • 10/22/26
Enlivex Announces Cost Reduction Plan to Focus Resources on Phase 2b Trial of Allocetra™ in Age-Related Primary Moderate-to-Severe Knee OsteoarthritisGlobeNewsWire • 10/19/26
Enlivex Announces Termination of Previously-Announced Financing Payable in RAIN TokensGlobeNewsWire • 09/22/26
Enlivex Ltd. (ENLV) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?Zacks Investment Research • 09/01/26
Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs JuneGlobeNewsWire • 07/30/26
Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical MilestonesGlobeNewsWire • 07/29/26
Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 BillionGlobeNewsWire • 07/20/26
Enlivex Ltd. (ENLV) Loses 31.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 07/13/26
Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee OsteoarthritisGlobeNewsWire • 07/13/26
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on Gate, One of the World's Largest Cryptocurrency Exchanges by Spot Trading VolumeGlobeNewsWire • 06/24/26
Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 BillionGlobeNewsWire • 06/22/26
Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with OsteoarthritisGlobeNewsWire • 06/15/26
ENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026GlobeNewsWire • 06/02/26
Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026GlobeNewsWire • 06/01/26
Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.16 Billion; Rain Foundation Appoints Industry Leaders to Advisory BoardGlobeNewsWire • 05/28/26
Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional LiquidityGlobeNewsWire • 05/27/26
Enlivex Announces Dosing Of First Patient In The United States As Part Of Its Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee OsteoarthritisGlobeNewsWire • 05/18/26
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on HTX, a Leading Cryptocurrency ExchangeGlobeNewsWire • 04/30/26